Loading...
Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
Nearly all patients with extensive-stage small-cell lung cancer (ES-SCLC) relapse following first-line etoposide plus platinum (EP) with or without immune checkpoint inhibition. Topotecan and amrubicin are chemotherapies approved for these patients. The toxicities of these chemotherapies are signifi...
Na minha lista:
| Udgivet i: | J Thorac Dis |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656348/ https://ncbi.nlm.nih.gov/pubmed/33209465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.03.67 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|